Acute myeloid leukemia trials in Italy

In Italy 61 Also abroad 761

61 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Bologna, Florence, Salerno, Verona
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Bologna, Meldola, Milan
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Ancona, Bologna, Civitanova Marche, Milan, Palermo, Perugia, Pescara, Rome, Salerno, Trieste, Turin
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
Phase 1Taking people
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Where
Bologna, Ravenna, Rome
Age
18 years and over
People
171 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT06001788 · EU 2023-510288-37-00
Phase 2/3Taking people
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Where
Bologna, Florence, Meldola, Ravenna, Rome, Rozzano
Age
18 years to 80 years
People
312 worldwide
Run by
Moleculin Biotech, Inc.
See details and how to joinNCT06788756 · EU 2024-518359-47-00
Phase 2Taking people
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Where
Bologna, Monza, Naples, Padova, Rome
Age
Up to 64 years
People
31 worldwide
Run by
Pediatric Research International GmbH
See details and how to join2025-521390-14-00 · EU 2025-521390-14-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Milan
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1/2Not yet taking people in Italy
Study testing a new experimental cell therapy in adults and children With Relapsed or Refractory Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm
Where
Bergamo, Monza
People
18
Run by
Fondazione Tettamanti
See details and how to join2025-524977-18-00 · EU 2025-524977-18-00
Phase 1Taking people
A Study to Assess Adverse Events and How Pivekimab Sunirine Moves Through the Body of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Where
Bologna, Rome
Age
Up to 17 years
People
18 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-520125-36-00 · EU 2024-520125-36-00
Phase 1/2Not yet taking people in Italy
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Bologna, Naples, Padova, Pavia, Rozzano
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
No phaseTaking people
Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions
Where
Florence
Age
18 years and over
People
220
Run by
Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT07080970
Phase 2Taking people
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone
Where
Castelfranco Veneto, Genoa, Meldola, Naples, Ravenna
Age
18 years and over
People
40 worldwide
Run by
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
See details and how to join2025-524308-31-00 · EU 2025-524308-31-00
No phaseTaking people
Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia
Where
Milan, Reggio Calabria
Age
18 years and over
People
80
Run by
Ciceri Fabio
See details and how to joinNCT06535113
Phase 3Taking people
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Where
Bari, Bergamo, Bologna, Brescia, Florence, Meldola, Milan, Perugia, Pesaro, Udine, Venice
Age
18 years and over
People
245 worldwide
Run by
Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00
No phaseTaking people
Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes
Where
Brescia
People
20
Run by
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
See details and how to joinNCT03058588
No phaseTaking people
Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
Where
Brescia
Age
18 years to 75 years
People
1,941
Run by
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
See details and how to joinNCT07420790
Phase 2Not yet taking people in Italy
Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia
Where
Perugia, Pescara
Age
18 years to 70 years
People
28
Run by
Antonio Pierini
See details and how to joinNCT07552649
Phase 2Taking people
A phase 2A pilot study to assess the safety and efficacy of eltanexor in relapsed/refractory NPM1-mutated acute myeloid leukemia
Where
Ancona, Catania, Perugia
Age
18 years and over
People
10
Run by
Azienda Ospedaliero Universitaria Delle Marche
See details and how to join2024-514724-16-01 · EU 2024-514724-16-01
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Bologna, Busto Arsizio, Genoa, Meldola, Padua, Perugia, Ravenna, Rome, Turin
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
No phaseTaking people
Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.
Where
Pavia
People
14
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT07254312
Phase 3Taking people
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Where
Lecce, Meldola, Pisa, Rome, Rozzano, Turin
Age
18 years and over
People
486 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06389292 · EU 2024-516436-10-00
Phase 3Taking people
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Where
Bologna, Milan, Roma, Torino
Age
18 years and over
People
227 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016
No phaseTaking people
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Where
San Giovanni Rotondo, Sassari
Age
18 years and over
People
397
Run by
Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT06513273
No phaseTaking people
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
Where
Milan
Age
18 years and over
People
500
Run by
Ciceri Fabio
See details and how to joinNCT05124288
Phase 2Taking people
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Where
Genoa, Rozzano
Age
18 years to 99 years
People
42
Run by
Istituto Clinico Humanitas
See details and how to joinNCT06892223 · EU 2024-516974-31-00